Psychiatric Medication for Adolescents: Consent, Safety and Follow-Up

Psychiatric medication for adolescents should follow an age-appropriate assessment and a plan that includes the young person's goals and understanding. Approved medicines and indications differ from adult practice. Follow-up needs to address symptoms, functioning, physical development, adverse effects, and safety while respecting appropriate privacy and involvement of caregivers.

Assessment should consider development and context

Mood, attention, behavior, and sleep can be influenced by school, relationships, trauma, substances, physical illness, and developmental needs. A diagnosis should not be inferred from one symptom or a difficult week. The assessment should identify impairment and consider coexisting conditions.

Ask what the young person wants to improve, such as attending school, participating in friendships, managing panic, or completing tasks. Caregiver and school information may help when appropriately shared. The plan should explain what information is confidential and when safety concerns require involvement of others.

Medication choices need an adolescent-specific rationale

A product may be approved for adults but not for a particular adolescent age or condition. Off-label prescribing can sometimes be appropriate, but the clinician should explain the evidence, uncertainty, alternatives, and monitoring. Adult treatment should not simply be copied at a different size.

For depression, psychological treatment has an important role, and selected antidepressants may be considered according to severity and guidance. ADHD medicines and antipsychotics have different indications and risks. Each prescription should have a clear target rather than being used broadly to control difficult behavior.

Discuss suicidality and early changes directly

Antidepressants carry an important warning about increased suicidal thoughts or behaviors in some younger people, particularly around starting or changing treatment. This requires active monitoring and clear contacts. It does not mean depression should remain untreated; the risks of the illness also matter.

New agitation, marked mood elevation, worsening distress, self-harm thoughts, or unusual behavior should be reported promptly. Immediate danger requires urgent help. The young person and relevant caregivers should know how to reach the team rather than being left to interpret changes alone.

Monitoring depends on the treatment

Support informed participation and practical use

Explain the medicine in language the young person can understand, including expected benefit, uncertainties, and unwanted effects. Invite questions and preferences. Consent requirements vary by location and circumstances, so the treating service should explain the applicable process rather than assuming one universal rule.

Discuss storage, missed doses, school administration where relevant, and pressure to share medicines. Substance use and supplements should be discussed without judgment. Practical barriers and side effects can explain inconsistent use and should prompt problem-solving rather than blame.

Review the need and plan transitions

Regular reviews should consider whether the original target remains relevant, whether treatment helps, and whether developmental or physical-health changes alter the balance. Psychological, family, school, and practical support remain important even when medication is effective.

Moving into adult services needs a medication list, monitoring history, and confirmed follow-up. Do not independently stop treatment as a birthday approaches or a service changes. Any reduction or switch should have clear instructions, continued support, and a way to respond to returning symptoms.

Make treatment goals meaningful to the young person

A treatment goal should describe an improvement the adolescent recognizes, such as attending school more consistently, spending less time on rituals or being able to concentrate on a chosen activity. Adults may focus on grades or visible behavior while the young person is struggling with anxiety, emotional pain or sleep. Discussing both perspectives helps avoid evaluating medication only through compliance. The diagnosis and treatment rationale should be explained in language the adolescent can understand, with time for questions and disagreement.

Set a baseline for the difficulties being treated and for important aspects of daily life. This might include sleep, appetite, friendships, activity and participation in therapy. A questionnaire can support review but should not replace the young person's account. Changes at home or school may also influence progress. For ADHD, information from more than one setting can help assess function, while protecting privacy. If the agreed goal does not improve, the team should reconsider the plan rather than simply assuming the young person needs to try harder.

Plan early contact and discuss safety without creating stigma

Before starting or changing an antidepressant, explain how emerging suicidal thoughts, agitation, unusual activation or worsening distress will be identified and addressed. The underlying illness also carries risk, so monitoring is part of treatment rather than proof that medication is always inappropriate. Young people should know they can report a difficult experience without being blamed or automatically losing all control over decisions. A clinician should explain the confidentiality arrangements and the circumstances in which information needs to be shared for safety.

Agree on the first review, the way to contact the service between appointments and what a parent or trusted adult should observe. Ask the adolescent how they prefer to communicate sensitive concerns. A written contact plan is more useful than simply saying to report side effects. Immediate risk of self-harm or a severe behavioral change needs urgent assessment. For ongoing but less acute problems, timely clinical contact can clarify whether the cause is illness, medication, withdrawal, another substance or a combination.

Keep monitoring specific to the prescribed treatment

The required checks differ between an ADHD medicine, an antidepressant and an antipsychotic. Ask which measurements or observations are needed and why. Growth, appetite, cardiovascular measures, sleep, mood or metabolic health may be relevant depending on the regimen. A medicine should not be described as fully monitored merely because one blood test was normal. Likewise, there is no need to assume every adolescent requires the same test schedule. The prescriber should document a plan suited to the product and individual history.

Include practical exposures such as energy drinks, vaping, alcohol, recreational drugs and nonprescription remedies in a nonjudgmental discussion. Adolescents may not think of these as part of the medicine list. New prescriptions from another service should also be checked. If swallowing, remembering treatment or taking a dose at school is difficult, ask about a suitable solution. Do not crush or change a modified-release product without advice. The antipsychotic overview and antidepressant overview can support understanding, while the adolescent's clinician should guide specific use.

Support independence and plan transfer to adult services

As the young person gains independence, responsibilities for prescriptions, appointments and monitoring may change. Check that they understand the medicine's purpose, where supplies come from and what to do if a dose is missed or a refill is delayed. This is also a chance to discuss treatment preferences, privacy and any concerns about dependence or stigma. Support should be adapted to the adolescent's needs rather than removed abruptly because of a birthday or a move away from home.

Before transfer to adult care, prepare a concise record of diagnosis, effective treatments, important adverse effects, previous trials and monitoring requirements. Confirm which service will prescribe during the handover and how to obtain urgent advice. Changes in education, employment or living arrangements may alter routines even when the medicine remains the same. A planned review can distinguish these practical barriers from a loss of treatment benefit. The transition should preserve access to psychological care and appropriate family or supporter involvement with the young person's agreement.

Making the next medication discussion useful

Bring one current list of medicines to the appointment, including the exact product, prescribed instructions, over-the-counter remedies, supplements and any medicines you take only occasionally. If the list in a clinic record is different from what you actually use, say so. Understanding the difference is more useful than trying to give an answer that sounds correct. A photograph of packaging can help clarify an unfamiliar brand or formulation.

Choose two or three priorities before the visit. These might be a persistent symptom, a side effect affecting daily life, a monitoring result or concern about continuing treatment. Describe when the problem began and whether it followed a change in medicine, illness, sleep or substance use. You do not have to diagnose the cause yourself. A clear timeline helps the clinician consider several explanations without automatically attributing everything to the psychiatric condition.

Leave with an agreed next step and a review date. If the plan changes, ask for written instructions that explain what each medicine is intended to do and whom to contact if a problem occurs. Check that the pharmacy and other prescribers have the updated plan. A useful review ends with responsibilities assigned, not simply with a recommendation to monitor the situation. Shared decisions should include your preferences, the available evidence and the practical ability to carry out the plan.

Related Medication and Treatment Guides

• What are Antipsychotics
• What are Antidepressants
• What is ADHD
• Explore the Medication Guide